(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/155087 A1

(51) International Patent Classification:
A61K 31/4162 (2006.01) *A61P 43/00* (2006.01)
A61P 1/16 (2006.01) *A61K 9/00* (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:
PCT/US2021/015614

(22) International Filing Date:
29 January 2021 (29.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/967,878 30 January 2020 (30.01.2020) US
63/029,971 26 May 2020 (26.05.2020) US

(71) Applicant: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: **BOZIC, Carmen**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CIRINCIONE, Brenda**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **HARE, Brian J.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **INGENITO, Edward**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **KUMAR, Sanjeev**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **MARIGOWDA, Gautham**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **PANORCHAN, Porntula**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **PETERSON, Mark Christopher**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **RHEE, David**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **STILES, David Kent**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **TIAN, Bosheng**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **ZHANG, Weiyan**; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: **MCDONELL, Leslie A.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: METHODS OF TREATMENT FOR ALPHA-1 ANTITRYPSIN DEFICIENCY

(57) Abstract: This application describes methods of treating alpha-1 antitrypsin deficiency (AATD) comprising administering Compound I, a deuterated derivative thereof, and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, and/or a pharmaceutically acceptable salt thereof.



Compound I

WO 2021/155087 A1